Sunitinib resistance in renal cell carcinoma

Sunitinib resistance in renal cell carcinoma

<p>Of the many targeted therapies introduced since 2006, sunitinib has carved its way to become the most commonly used first-line therapy for the treatment of metastatic renal cell carcinoma (RCC). Despite significant improvements in progression-free survival, 30% of the patients are intrinsic...

Full description

Bibliographic Details
Main Author:	Christudas Morais
Format:	Article
Language:	English
Published:	Codon Publications 2014-04-01
Series:	Journal of Kidney Cancer and VHL
Subjects:	renal cell carcinoma sunitinib resistance kidney cancer
Online Access:	http://jkcvhl.com/index.php/jkcvhl/article/view/7

Similar Items

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
by: Tomonori Sato, et al.
Published: (2020-12-01)

Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma
by: Se Woong Choi, et al.
Published: (2020-02-01)

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
by: Kaamar Azijli, et al.
Published: (2016-01-01)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
by: Harrison Sicheng Lin, et al.
Published: (2022-01-01)

Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma
by: Liping Shan, et al.
Published: (2020-09-01)

Corrigendum: Long non-coding RNA CCAT1 acts as an oncogene and promotes sunitinib resistance in renal cell carcinoma
by: Liping Shan, et al.
Published: (2023-08-01)

Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients
by: Romualdo Barroso-Sousa, et al.
Published: (2014-12-01)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
by: Akihiro Yoshimura, et al.
Published: (2020-09-01)

Key sunitinib‐related biomarkers for renal cell carcinoma
by: Yun Peng, et al.
Published: (2021-10-01)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
by: Jun Guo, et al.
Published: (2018-05-01)

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
by: Magdalena Rausch, et al.
Published: (2021-06-01)

Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study
by: El-Hadaad Hend Ahmed, et al.
Published: (2015-12-01)

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
by: Xinan Sheng, et al.
Published: (2020-03-01)

Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
by: Zeshen Wu, et al.
Published: (2022-10-01)

The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
by: Rafia S. Al-Lamki, et al.
Published: (2020-04-01)

PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
by: Chenchen Feng, et al.
Published: (2021-09-01)

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
by: Cheng-Yuan Gu, et al.
Published: (2021-10-01)

Interaction between Wnt/β-catenin signaling pathway and EMT pathway mediates the mechanism of sunitinib resistance in renal cell carcinoma
by: Fangzhen Cai, et al.
Published: (2024-02-01)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
by: Antonello Di Paolo, et al.
Published: (2017-08-01)

Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway
by: Sascha D. Markowitsch, et al.
Published: (2022-02-01)

Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment
by: Utku Oflazoglu, et al.
Published: (2016-08-01)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
by: Fiala O, et al.
Published: (2021-05-01)

Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment
by: Kouki Tada, et al.
Published: (2023-01-01)

Sunitinib maleate administration before percutaneous CT-guided cryoablation for large renal cell carcinoma: A case report
by: Kaori Nishizawa, MD, et al.
Published: (2022-12-01)

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
by: Yuang Wei, et al.
Published: (2021-07-01)

Suppression of SREBP-1 Expression by Simvastatin Decreases Visfatin-Induced Chemoresistance to Sunitinib in Human Renal Carcinoma 786-O Cells
by: Te-Chuan Chen, et al.
Published: (2022-11-01)

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study
by: Bibian M. E. Tullemans, et al.
Published: (2022-06-01)

Catfish Egg Lectin Enhances the Cytotoxicity of Sunitinib on Gb3-Expressing Renal Cancer Cells
by: Jun Ito, et al.
Published: (2023-08-01)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
by: Haohao Lu, et al.
Published: (2023-03-01)

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro
by: Igor Tsaur, et al.
Published: (2022-09-01)

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
by: Amishi Y. Shah, et al.
Published: (2015-03-01)

Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC)
by: María Armesto, et al.
Published: (2021-08-01)

miRNA-381 regulates renal cancer stem cell properties and sunitinib resistance via targeting SOX4
by: Xiao-jun Lu, et al.
Published: (2023-12-01)

Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report
by: Maria Massucci, et al.
Published: (2021-01-01)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
by: Nicolas S. H. Xander, et al.
Published: (2023-06-01)

Gallbladder Metastasis from Renal Cell Carcinoma
by: Takashi Kawahara, et al.
Published: (2010-01-01)

Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
by: Bo Peng, et al.
Published: (2017-05-01)

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
by: Viktor Grünwald, et al.
Published: (2023-08-01)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
by: Zhu X, et al.
Published: (2021-08-01)

Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma
by: Fengjun Sun, et al.
Published: (2021-03-01)